Dimerix Ltd has released a press release.
DMX-700 Study Shows Significant 80% Reduction in Lung Injury
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- REMAP-CAP COVID-19 Study Analysis Update
- New Clinical Trial for DMX-200 in Diabetic Kidney Disease
- Phase 3 FSGS Kidney Trial First Patient Recruited
- Dimerix presentation at Bioshares Biotech Summit
- FDA IND Approval for Phase 3 Study of DMX-200 in FSGS
Later from Dimerix
- New Patent Family Application for DMX-700
- CLARITY 2.0 COVID-19 Study Concludes Recruitment
- Appendix 4E and 2022 Annual Report
- Dimerix Receives A$6.0M R&D Tax Incentive Rebate
- Chair address and CEO presentation to AGM
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix